Every SEC Form 3/4/5 on record for this filer (CIK 1414815) — 6 issuers, 54 transactions. Section-16 filings only: what they filed, not a biography, and titles are as filed on their latest form at each issuer.
| Ticker | Company | Role as filed | On file | Forms | Open-market net |
|---|---|---|---|---|---|
| CRL | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | Director | 2017-07-07 → 2026-05-11 | 14 | — |
| KLRA | Kailera Therapeutics, Inc. | Director | 2026-04-16 → 2026-04-20 | 2 | — |
| RLYB | Rallybio Corp | Director | 2021-07-29 → 2026-02-20 | 8 | $103,473 |
| SWTX | SpringWorks Therapeutics, Inc. | Director | 2024-07-30 → 2025-07-02 | 4 | — |
| FVAM | 5:01 Acquisition Corp. | Director · lapsed | 2020-10-13 → 2020-10-20 | 2 | — |
| ALXN | ALEXION PHARMACEUTICALS INC | EVP & Global Head of R&D · lapsed | 2015-08-05 → 2017-03-01 | 7 | −$10M |
No open-market buy or sale on record — only grants, exercises, withholding or gifts. Switch to “All forms” to see them.
3 of 6 issuers are covered and open a security page; the rest are on file here only.
